The protective effects of SA3443, a novel cyclic disulfide, on chronic liver injuries in rats.
The effects of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4- carboxylic acid (SA3443), a novel cyclic disulfide compound, on the development of chronic liver injury were studied in rats, using two types of models, carbon tetrachloride (CCl4)-induced chronic liver injury and heterologous serum (swine serum)-induced liver fibrosis. SA3443 (30-100 mg/kg, p.o.) significantly suppressed increases in serum transaminase and alkaline phosphatase activity induced by CCl4-treatment for 10 weeks. This compound also inhibited increases in hepatic lipids and hydroxyproline content in CCl4-treated rats. In the histopathological studies, treatment with SA3443 resulted in a decrease in the degree of hepatic necrosis, fibrosis and steatosis. On the other hand, 8-weeks treatment with swine serum revealed hepatic fibrosis without appearance of necrosis or fatty accumulation. In this model, SA3443 (30 mg/kg, p.o.) reduced the hepatic hydroxyproline level, and diminished the formation of connective tissue in the liver. These findings indicate that SA3443 protects the liver against chronic liver injuries induced by CCl4 and heterogeneous serum.
Ishida
N
N
Central Research Laboratories, Santen Pharmaceutical Co. Ltd., Osaka, Japan.
Nakata
K
K
Takase
K
K
Tanaka
M
M
Mita
S
S
D000818:Animals; D001392:Azocines / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D002908:Chronic Disease; D004220:Disulfides / Q000627:therapeutic use*; D008106:Liver Cirrhosis, Experimental / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D015394:Molecular Structure; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
D001392:Azocines; D004220:Disulfides; C069788:SA 3443